Skip to main content

Table 1 Baseline characteristics of patients in the low-dose and standard-dose groups

From: Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Characteristics Low-dose
(n = 36)
Standard-dose
(n = 45)
P-value
Age (years), median (IQR) 67 (59–76) 67 (60–76) 0.850
Male sex, n (%) 25 (69.4) 27 (60.0) 0.490
Weight (kg), median (IQR) 57.4 (50.0–64.8) 56.1 (50.0–63.9) 0.530
Underlying disease, n (%)    < 0.001
 Hematological malignancy, n (%) 18 (50.0) 5 (11.1)  
 Leukemia, n (%) 5 (13.9) 0 (0.0)  
 Lymphoma, n (%) 6 (16.7) 3 (6.7)  
 Multiple myeloma, n (%) 7 (19.4) 2 (4.4)  
 Autoimmune disease, n (%) 12 (33.3) 33 (73.3)  
 Connective tissue disease, n (%) 6 (16.7) 4 (8.9)  
 Polyangiitis, n (%) 3 (8.3) 14 (31.1)  
 Nephritis, n (%) 2 (5.6) 15 (33.3)  
 ITP, n (%) 1 (2.8) 0 (0.0)  
 Others a, n (%) 6 (16.7) 7 (15.6)  
Treatment for each underlying disease    < 0.001
 Hematological malignancy
  Chemotherapy, n (%) 6 (16.7) 2 (4.4)  
  Chemotherapy with corticosteroid, n (%) 11 (30.5) 3 (6.7)  
  Immunosuppressive agent, n (%) 1 (2.8) 0 (0.0)  
 Autoimmune disease, n (%)
  Corticosteroid, n (%) 11 (30.6) 33 (73.3)  
  Immune suppressive drug, n (%) 1 (2.8) 0 (0.0)  
 Others
  Corticosteroid, n (%) 5 (13.9) 7 (15.6)  
  Chemotherapy, n (%) 1 (2.8) 0 (0.0)  
Dose of corticosteroid (mg)b, median (IQR) 25.0 (16.6–40.0) 35 (25.0–44.5) 0.212
 Dose of corticosteroid in patients with Hematological malignancy 23.8 (18.6–38.0) 24.0 (23.9–31.0)  
 Dose of corticosteroid in patients with autoimmune disease 25.0 (20.0–45.0) 35.0 (25.0–45.0)  
 Dose of corticosteroid in patients with other disease 40.0 (13.0–50.0) 30.0 (20.0–47.0)  
Total bilirubin (mg/dL), median (IQR) 0.4 (0.3–0.5) 0.4 (0.3–0.6) 0.626
ALT (IU/L), median (IQR) 16.5 (8.0–42.5) 13.0 (9.0–26.0) 0.631
AST (IU/L), median (IQR) 14.8 (7.0–35.3) 14.8 (13.0–24.0) 0.143
White blood cell (× 103/μL), median (IQR) 7.5 (5.2–11.8) 8.5 (6.7–11.2) 0.206
Hemoglobin (g/dL), median (IQR) 9.65 (8.8–11.3) 9.9 (9.0–11.6) 0.450
Platelet (× 104/μL), median (IQR) 15.7 (11.8–25.4) 18.7 (14.8–25.6) 0.150
  1. Categorical variables were summarized as counts and percentages, and continuous variables were summarized as medians and interquartile ranges (quartiles 1–3). P values were determined using the chi-squared exact test for categorical variables and the Mann-Whitney U test for continuous variables
  2. Abbreviations: IQR interquartile range, ITP idiopathic thrombocytopenic purpura, ALT alanine aminotransferase, AST aspartate aminotransferase
  3. a Others included eosinophilia, Lung disease, drug eruption, adrenal cortex insufficiency, encephaloma and aldosteronism
  4. b Corticosteroid doses are expressed in Prednisolone (PSL) equivalents